List of Excipients in Branded Drug ATRACURIUM BESYLATE

« Back to Dashboard

Generic Drugs Containing ATRACURIUM BESYLATE

Company	Ingredient	NDC	Excipient
Hospira Inc	atracurium besylate	0409-1105	BENZENESULFONIC ACID
Hospira Inc	atracurium besylate	0409-1105	BENZYL ALCOHOL
Sagent Pharmaceuticals	atracurium besylate	25021-659	BENZENESULFONIC ACID

What are the Most Frequently-Used Excipients in ATRACURIUM BESYLATE?

# Of NDCs	Excipient
5	BENZENESULFONIC ACID
2	BENZYL ALCOHOL
4	WATER

Atracurium Besylate Excipient Strategy and Commercial Opportunities

Last updated: September 9, 2026

Atracurium besylate is a mature, injectable neuromuscular-blocking agent with limited active pharmaceutical ingredient differentiation. Commercial value is concentrated in formulation reliability, cold-chain performance, container-closure systems, shortage-resistant supply, and hospital-use convenience rather than in new chemical-entity exclusivity. The core formulation is a sterile aqueous solution, typically containing atracurium besilate, water for injection, and an acidifying agent such as benzenesulfonic acid. [1][2]

What is the approved formulation of atracurium besylate injection?

Atracurium besylate injection is generally supplied as a 10 mg/mL sterile solution for intravenous administration. The reference product, Tracrium, uses a strongly acidic formulation designed to support chemical stability.

Formulation attribute	Typical position
Active ingredient	Atracurium besilate
Strength	10 mg/mL
Route	Intravenous
Dosage form	Sterile solution
Primary solvent	Water for injection
pH control	Benzenesulfonic acid or equivalent acidifying system
Preservative	Typically preservative-free single-dose presentation
Storage	Refrigerated storage, generally 2°C to 8°C
Administration	Intravenous bolus or infusion after dilution where appropriate
Main users	Hospitals, operating rooms, intensive-care units and emergency departments

Atracurium undergoes Hofmann elimination and ester hydrolysis. Its degradation profile is influenced by temperature, pH, light exposure, oxygen, container materials and storage duration. The formulation must preserve potency without creating unacceptable degradation products or causing administration-related irritation. [1][2]

Which excipients are most important for atracurium besylate?

Acidifying agents

Benzenesulfonic acid is used in established atracurium injection formulations. The acidifying system supports a low-pH environment that helps maintain product stability during refrigerated storage.

A reformulator should evaluate:

• pH drift over shelf life
• atracurium assay and related substances
• compatibility with elastomeric closures
• extractables and leachables
• particulate formation
• compatibility after dilution into common infusion fluids

Substitution with hydrochloric acid, sulfuric acid or another pharmaceutically acceptable acid may be technically possible, but it would require comparative stability, impurity, local-tolerance and container-closure data. A different acid system may affect degradation kinetics and regulatory comparability.

Water for injection

Water for injection is the principal vehicle. The vehicle must comply with compendial requirements for sterility, endotoxins, conductivity and total organic carbon. The commercial opportunity is not the vehicle itself but control of the complete sterile manufacturing process.

Tonicity modifiers

Some generic products or alternative presentations may use sodium chloride to improve tonicity. The decision requires a balance between injection comfort, osmolality, chemical stability and compatibility with the final container.

A sodium-chloride-containing presentation could be commercially useful if it reduces bedside dilution or provides a ready-to-administer product. It also creates a larger excipient burden and may increase the need for formulation and compatibility studies.

Buffers

Conventional phosphate or citrate buffers are not automatically attractive for atracurium. Buffer systems can alter pH, ionic strength and degradation behavior. A buffered formulation would need to demonstrate a clear benefit over the established acidic solution.

The principal risks include:

• Faster degradation at the target pH
• New impurity pathways
• Reduced compatibility with infusion solutions
• Greater risk of precipitation after dilution
• More complex regulatory justification

Preservatives

A preservative-free, single-dose vial is generally preferable for operating-room and intensive-care use. Multidose presentations could reduce packaging cost, but preservatives may introduce toxicity, compatibility and regulatory issues. Benzyl alcohol, phenol and parabens would require particular scrutiny because of neonatal, pediatric and critically ill patient considerations.

What formulation patents protect atracurium besylate?

Atracurium is a mature small-molecule product. The original composition-of-matter and early pharmaceutical development patents are expected to be expired in major markets. Commercial protection for standard atracurium injection therefore does not normally depend on an active basic-molecule patent.

IP category	Commercial relevance
Composition-of-matter patents	Generally expired for this mature active ingredient
Original formulation patents	Generally expired or commercially weak
Standard sterile injection	Usually exposed to generic competition
New ready-to-use presentation	Potentially protectable through formulation, packaging or method claims
Device-enabled administration	Potentially protectable through device or combination-product claims
Manufacturing process	May support trade-secret protection or narrow process claims
Stability-improving excipient system	Potential opportunity if technically non-obvious and clinically useful
Container-closure system	Potential patent and know-how value
Labeling and method-of-use claims	Limited value unless tied to a differentiated clinical use

The relevant IP opportunity is a secondary patent estate directed to a technically demonstrated improvement. Candidates include room-temperature stability, premixed infusion bags, low-volume high-concentration presentations, prefilled syringes, reduced adsorption, oxygen control, improved light protection, or a formulation that remains stable after dilution.

A patent filing would require more than the selection of a conventional excipient. A defensible claim would need comparative data showing an unexpected stability, usability or safety advantage over the reference formulation and reasonable alternatives.

What is the Orange Book status of atracurium besylate?

Atracurium besylate injection is a genericized injectable product with no meaningful new-drug exclusivity profile comparable to recently approved medicines. FDA Orange Book analysis should distinguish:

1. The reference listed drug and its approval history.
2. Approved abbreviated new drug applications.
3. Any listed patents.
4. Any pediatric exclusivity or regulatory exclusivity.
5. Product-specific labeling and dosage-form differences.

Established atracurium injection products generally compete through abbreviated new drug applications rather than through active innovator exclusivity. FDA approval depends on pharmaceutical equivalence, bioequivalence where applicable, sterile manufacturing controls, labeling and quality requirements. [3][4]

A company developing a new presentation should not assume that the absence of basic-molecule exclusivity eliminates regulatory complexity. A premixed bag, prefilled syringe or novel container may require additional compatibility, extractables, sterility, in-use stability and administration data.

When does atracurium besylate lose exclusivity?

The original chemical and formulation exclusivity for atracurium is long expired in the United States and other major pharmaceutical markets. The product is commercially open to generic competition, subject to applicable regulatory approvals and manufacturing capacity.

The main barriers are operational rather than exclusivity-based:

• Sterile injectable manufacturing capacity
• Reliable supply of atracurium active ingredient
• Validation of low-pH product-contact materials
• Refrigerated distribution
• Hospital contracting
• Shortage-management requirements
• Pharmacovigilance and quality-system performance

Paragraph IV challenges are not the primary commercial issue for a mature product with no significant active patent barrier. A new applicant would more commonly pursue an ANDA pathway addressing the listed reference product and any remaining patent certifications. [3]

What excipient strategies create commercial differentiation?

Room-temperature stability

The most valuable technical objective is an atracurium presentation with validated stability outside the conventional refrigerated range. This could reduce hospital waste, simplify emergency-stock management and improve distribution in markets with weak cold-chain infrastructure.

The development burden is high. Data would need to cover long-term, accelerated and excursion conditions, with testing for potency, degradation products, appearance, particulate matter, sterility and container-closure integrity.

Ready-to-use infusion products

A premixed infusion bag could reduce pharmacy preparation, dose calculation and handling time. Potential formats include:

• Atracurium in sodium chloride injection
• Atracurium in dextrose-containing solutions
• Small-volume infusion containers
• Pharmacy bulk or institutional presentations

The formulation must address adsorption, dilution stability, infusion-line compatibility and microbial-control requirements. The commercial value is highest in hospitals that use continuous neuromuscular blockade in intensive-care settings.

Prefilled syringes

A prefilled syringe could target emergency departments, anesthesia carts and standardized operating-room workflows. Advantages include reduced preparation steps, lower vial waste and improved dose consistency.

Key development issues include syringe-material compatibility, silicone oil, plunger movement, needle integrity, extractables and shelf-life performance. The product would face higher packaging costs than a conventional vial.

Low-waste presentations

Smaller vial sizes or unit-dose formats could reduce waste when a full 10 mL vial is not needed. The opportunity depends on demand density and hospital purchasing behavior. Unit-dose packaging may command a premium where pharmacy labor and medication-safety costs are material.

Advanced container-closure systems

The container can provide meaningful differentiation through:

• Low-permeability elastomers
• Improved low-temperature performance
• Reduced adsorption
• Lower extractables and leachables
• Integrated light protection
• Terminally sterilizable packaging where feasible

These improvements are more likely to support trade-secret and product-quality advantages than broad patent protection unless combined with a novel formulation or system architecture.

How strong is the atracurium patent estate?

The basic patent estate is weak from a new-product perspective because the molecule and conventional injection are mature. A secondary estate could be moderate if it combines:

• A defined excipient concentration range
• A demonstrated stability advantage
• A specific pH window
• A novel container-closure system
• A validated room-temperature excursion profile
• A commercially relevant ready-to-use dosage form

Patent strength would be reduced if the claims merely recite routine sterile aqueous formulation techniques or predictable acidification. Broad claims covering atracurium with common pharmaceutical excipients would face enablement, written-description, obviousness and anticipation risks.

Trade-secret protection may be more practical for mixing order, oxygen control, filling parameters, sterilization strategy and impurity-control methods.

What regulatory risks affect atracurium excipient innovation?

FDA scrutiny would focus on product quality and clinical usability rather than on the novelty of the excipient itself. Relevant expectations include:

• Sterility assurance
• Bacterial endotoxin control
• Particulate matter
• Container-closure integrity
• Stability-indicating analytical methods
• Extractables and leachables
• Dilution and admixture compatibility
• In-use stability
• Labeling for storage and administration
• Human factors for prefilled or ready-to-use systems

FDA guidance on injectable drug products and container-closure systems is directly relevant to a differentiated atracurium presentation. [5][6]

Which companies are positioned to compete?

Competition is likely to come from established injectable manufacturers, generic suppliers and contract development and manufacturing organizations rather than from biotechnology companies. The relevant competitive capabilities are:

Capability	Strategic value
Sterile vial filling	Core requirement for conventional generic entry
Premix manufacturing	Enables hospital-convenience differentiation
Prefilled syringe production	Supports emergency and anesthesia channels
Refrigerated logistics	Necessary for conventional products
Global regulatory infrastructure	Expands market access
Hospital contracting	Determines formulary penetration
Shortage-response capacity	Creates procurement leverage
Analytical impurity expertise	Supports shelf-life and process control

A company with unused sterile capacity may have a stronger commercial position than a company with superior excipient science but no validated injectable platform.

What revenue exposure and market opportunity exist?

Atracurium is unlikely to support premium pricing as a conventional vial because multiple generic alternatives and competing neuromuscular blockers constrain pricing. Commercial opportunity is greater in differentiated formats:

1. Ready-to-administer hospital products.
2. Reliable supply during injectable shortages.
3. Room-temperature or extended-excursion products.
4. Premixed ICU infusion products.
5. Regional supply in markets with limited sterile manufacturing.
6. Contract manufacturing and private-label supply.

Revenue exposure is concentrated in institutional purchasing. Retail pharmacy demand is limited because atracurium is administered in controlled clinical settings.

How does atracurium compare with other neuromuscular blockers?

Product	Formulation opportunity	Commercial consideration
Atracurium besylate	Stability, premix, prefilled syringe, low-waste vial	Mature and price-sensitive
Cisatracurium besilate	Similar injectable strategy, often premium clinical positioning	May support higher value per unit
Rocuronium bromide	Ready-to-use and shortage-resilient supply	Broad anesthesia demand
Vecuronium bromide	Reconstitution and packaging convenience	More preparation burden
Succinylcholine chloride	Stability and emergency-use packaging	Distinct clinical role and storage constraints

Atracurium’s principal formulation advantage is its established acidic aqueous injection and predictable hospital use. Its main commercial weakness is limited differentiation in a crowded generic injectable category.

Key Takeaways

• Atracurium besylate is a mature sterile injectable with expired foundational exclusivity.
• The standard excipient strategy is simple: water for injection plus an acidic stabilizing system, commonly benzenesulfonic acid.
• The strongest commercial opportunities are room-temperature stability, premixed infusion products, prefilled syringes and low-waste unit-dose packaging.
• Conventional excipient substitution alone is unlikely to create durable patent value.
• Secondary patents require comparative stability, usability or safety data.
• Trade secrets may provide better protection for sterile manufacturing and impurity-control processes.
• FDA and hospital adoption risks center on sterility, stability, container compatibility, administration convenience and supply reliability.
• A differentiated atracurium product should compete on total hospital cost and availability rather than API novelty.

FAQs

Can atracurium besylate be formulated without benzenesulfonic acid?

Yes, but an alternative acidifying or buffering system would require comparative stability, impurity, compatibility and regulatory data. Benzenesulfonic acid is part of the established formulation approach.

Is a room-temperature atracurium product commercially attractive?

Yes. It could reduce cold-chain costs, improve emergency-stock management and expand use in markets with unreliable refrigeration. The product would need robust long-term and excursion stability data.

Can atracurium be sold in a prefilled syringe?

Potentially. The main technical issues are syringe-material compatibility, extractables, plunger performance, particulate control, sterility and shelf-life validation.

Are atracurium formulation patents likely to block generic entry?

Basic atracurium generic entry is unlikely to face a strong foundational patent barrier. A later entrant could encounter product-specific patents covering a novel premix, container, device or stability-enhancing formulation.

Which excipient strategy has the highest commercial potential?

A preservative-free, ready-to-use atracurium presentation with extended refrigerated stability or validated room-temperature excursions offers the clearest combination of hospital utility and defensible product differentiation.

References

1. U.S. Food and Drug Administration. (2011). Tracrium (atracurium besylate) injection prescribing information.
2. National Library of Medicine. (2024). DailyMed: Atracurium besylate injection.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (2014). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice.
6. U.S. Food and Drug Administration. (1999). Container closure systems for packaging human drugs and biologics.